This is an open-label to double-blind study evaluating the effects of cannabidiol (CBD) for the treatment of anxiety in adults. Participants will use a sublingual (under-the-tongue) solution of whole plant-derived CBD or placebo three times daily for four weeks in addition to their normal treatment regimen. Participants' clinical state will be assessed weekly during the treatment period. In addition, cognitive function and measures of quality of life, sleep, and general health will be assessed at baseline and the post-treatment final visit.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change From Baseline in Self-Reported Anxiety as Assessed by the Beck Anxiety Inventory (BAI)
Timeframe: 4 Weeks
Change From Baseline in Anxiety Assessed by the Overall Anxiety Severity and Impairment Scale (OASIS)
Timeframe: 4 Weeks
Change From Baseline in Self-Reported Anxiety Assessed by the State-Trait Anxiety Inventory (STAI)
Timeframe: 4 Weeks
Change From Baseline in Anxiety Measured by the Hamilton Anxiety Scale (HAM-A)
Timeframe: 4 Weeks